NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines

William G. Wierda; Andrew D. Zelenetz; Leo I. Gordon; Jeremy S. Abramson; Ranjana H. Advani; C. Babis Andreadis; Nancy Bartlett; John C. Byrd; Paolo Caimi; Luis E. Fayad; Richard I. Fisher; Martha J. Glenn; Thomas M. Habermann; Nancy Lee Harris; Francisco Hernandez-Ilizaliturri; Richard T. Hoppe; Steven M. Horwitz; Mark S. Kaminski; Christopher R. Kelsey; Youn H. Kim; Susan Krivacic; Ann S. LaCasce; Michael G. Martin; Auayporn Nademanee; Pierluigi Porcu; Oliver Press; Rachel Rabinovitch; Nishitha Reddy; Erin Reid; Kenneth Roberts; Ayman A. Saad; Erin D. Snyder; Lubomir Sokol; Lode J. Swinnen; Julie M. Vose; Joachim Yahalom; Mary A. Dwyer; Hema Sundar

doi:10.6004/jnccn.2017.0030

NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines

William G. Wierda, Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Paolo Caimi, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. KimSusan Krivacic, Ann S. LaCasce, Michael G. Martin, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Erin D. Snyder, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Mary A. Dwyer, Hema Sundar

Research output: Contribution to journal › Review article › peer-review

51 Scopus citations

Abstract

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmunotherapy regimens. More recently, small molecule inhibitors targeting kinases involved in a number of critical signaling pathways and a small molecule inhibitor of the BCL-2 family of proteins have demonstrated activity for the treatment of patients with CLL/SLL. These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/ SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL.

Original language	English
Pages (from-to)	293-311
Number of pages	19
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	15
Issue number	3
DOIs	https://doi.org/10.6004/jnccn.2017.0030
State	Published - Mar 1 2017

Access to Document

10.6004/jnccn.2017.0030

Cite this

Wierda, W. G., Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Caimi, P., Fayad, L. E., Fisher, R. I., Glenn, M. J., Habermann, T. M., Harris, N. L., Hernandez-Ilizaliturri, F., Hoppe, R. T., Horwitz, S. M., Kaminski, M. S., Kelsey, C. R., ... Sundar, H. (2017). NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 15(3), 293-311. https://doi.org/10.6004/jnccn.2017.0030

@article{53aa2788ec364f00a55c02409a8026de,

title = "NCCN guidelines{\textregistered} insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines",

abstract = "Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmunotherapy regimens. More recently, small molecule inhibitors targeting kinases involved in a number of critical signaling pathways and a small molecule inhibitor of the BCL-2 family of proteins have demonstrated activity for the treatment of patients with CLL/SLL. These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/ SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL.",

author = "Wierda, {William G.} and Zelenetz, {Andrew D.} and Gordon, {Leo I.} and Abramson, {Jeremy S.} and Advani, {Ranjana H.} and Andreadis, {C. Babis} and Nancy Bartlett and Byrd, {John C.} and Paolo Caimi and Fayad, {Luis E.} and Fisher, {Richard I.} and Glenn, {Martha J.} and Habermann, {Thomas M.} and Harris, {Nancy Lee} and Francisco Hernandez-Ilizaliturri and Hoppe, {Richard T.} and Horwitz, {Steven M.} and Kaminski, {Mark S.} and Kelsey, {Christopher R.} and Kim, {Youn H.} and Susan Krivacic and LaCasce, {Ann S.} and Martin, {Michael G.} and Auayporn Nademanee and Pierluigi Porcu and Oliver Press and Rachel Rabinovitch and Nishitha Reddy and Erin Reid and Kenneth Roberts and Saad, {Ayman A.} and Snyder, {Erin D.} and Lubomir Sokol and Swinnen, {Lode J.} and Vose, {Julie M.} and Joachim Yahalom and Dwyer, {Mary A.} and Hema Sundar",

year = "2017",

month = mar,

day = "1",

doi = "10.6004/jnccn.2017.0030",

language = "English",

volume = "15",

pages = "293--311",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "3",

}

Wierda, WG, Zelenetz, AD, Gordon, LI, Abramson, JS, Advani, RH, Andreadis, CB, Bartlett, N, Byrd, JC, Caimi, P, Fayad, LE, Fisher, RI, Glenn, MJ, Habermann, TM, Harris, NL, Hernandez-Ilizaliturri, F, Hoppe, RT, Horwitz, SM, Kaminski, MS, Kelsey, CR, Kim, YH, Krivacic, S, LaCasce, AS, Martin, MG, Nademanee, A, Porcu, P, Press, O, Rabinovitch, R, Reddy, N, Reid, E, Roberts, K, Saad, AA, Snyder, ED, Sokol, L, Swinnen, LJ, Vose, JM, Yahalom, J, Dwyer, MA & Sundar, H 2017, 'NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 15, no. 3, pp. 293-311. https://doi.org/10.6004/jnccn.2017.0030

NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines. / Wierda, William G.; Zelenetz, Andrew D.; Gordon, Leo I. et al.
In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 15, No. 3, 01.03.2017, p. 293-311.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017

T2 - Featured updates to the NCCN guidelines

AU - Wierda, William G.

AU - Zelenetz, Andrew D.

AU - Gordon, Leo I.

AU - Abramson, Jeremy S.

AU - Advani, Ranjana H.

AU - Andreadis, C. Babis

AU - Bartlett, Nancy

AU - Byrd, John C.

AU - Caimi, Paolo

AU - Fayad, Luis E.

AU - Fisher, Richard I.

AU - Glenn, Martha J.

AU - Habermann, Thomas M.

AU - Harris, Nancy Lee

AU - Hernandez-Ilizaliturri, Francisco

AU - Hoppe, Richard T.

AU - Horwitz, Steven M.

AU - Kaminski, Mark S.

AU - Kelsey, Christopher R.

AU - Kim, Youn H.

AU - Krivacic, Susan

AU - LaCasce, Ann S.

AU - Martin, Michael G.

AU - Nademanee, Auayporn

AU - Porcu, Pierluigi

AU - Press, Oliver

AU - Rabinovitch, Rachel

AU - Reddy, Nishitha

AU - Reid, Erin

AU - Roberts, Kenneth

AU - Saad, Ayman A.

AU - Snyder, Erin D.

AU - Sokol, Lubomir

AU - Swinnen, Lode J.

AU - Vose, Julie M.

AU - Yahalom, Joachim

AU - Dwyer, Mary A.

AU - Sundar, Hema

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmunotherapy regimens. More recently, small molecule inhibitors targeting kinases involved in a number of critical signaling pathways and a small molecule inhibitor of the BCL-2 family of proteins have demonstrated activity for the treatment of patients with CLL/SLL. These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/ SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL.

AB - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmunotherapy regimens. More recently, small molecule inhibitors targeting kinases involved in a number of critical signaling pathways and a small molecule inhibitor of the BCL-2 family of proteins have demonstrated activity for the treatment of patients with CLL/SLL. These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/ SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL.

UR - http://www.scopus.com/inward/record.url?scp=85016166539&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2017.0030

DO - 10.6004/jnccn.2017.0030

M3 - Review article

C2 - 28275031

AN - SCOPUS:85016166539

SN - 1540-1405

VL - 15

SP - 293

EP - 311

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 3

ER -

NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this